Company

Mirati Therapeutics

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 14, 2026 · PHASE 3 TRIAL

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; the study is actively recruiting and outcomes are not yet reported.

PreliminaryMirati Therapeutics Adagrasib Carcinoma, Non Small Cell Lung

Reported

Planned enrollment630

Primary endpoint 1Progression Free Survival (PFS) as assessed…

Primary endpoint 2Overall Survival (OS), up to 7 years

AUG 11, 2026 · PHASE 3 TRIAL

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

ClinicalTrials.gov

This is a clinical trial registry record describing a planned or ongoing Phase 3 study with no results posted; efficacy and safety data are not yet available in this source.

PreliminaryNCT04685135 Metastatic Non Small Cell Lung Cancer Mirati Therapeutics

Reported

Planned enrollment453

Primary outcome measureProgression-Free Survival (PFS) as Per Blin…

PFS follow-up durationup to approximately 143 weeks